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Abstract
Background: Cocaine abuse is associated with several mechanisms of brain injury including ischemic, hemorrhagic
and metabolic. Recently two case reports of leukoencephalopathy in cocaine users implicated a commonly used
cocaine adulterant, levamisole. One well-documented adverse effect of levamisole, when used alone as antihelminthic
or immunomodulatory drug, is multifocal inflammatory leukoencephalopathy. Therefore, immune mechanisms may
also contribute to cocaine-induced brain injury.
Case presentations: Two cocaine users with multifocal leukoencephalopathy, treated with steroids and
plasmapheresis, are described. The first is a 25-year-old man who presented with unilateral motor and sensory
impairment progressing to bilateral deficits, dysphagia, dysarthria and confusion over several days. Serial MRI
showed increasing abnormal FLAIR signal lesions with patchy restricted diffusion and heterogenous enhancement
deep in the right and left hemispheres, including periventricular white matter as well as in the pons and cerebellar
peduncle. The second patient is a 41-year-old woman who presented with confusion and impaired balance. MRI
showed bilateral periventricular FLAIR lesions with scattered restricted diffusion and subtle gadolinium enhancement of
some of the lesions. She initially stabilized with supportive care only, but after further cocaine use was re-admitted six
weeks later with marked neurological deterioration and MRI showed prominent worsening of the lesions. Both patients
received steroid and plasma exchange and showed substantial improvement clinically and on imaging, which was
sustained during out-patient follow-up.
Conclusion: Multifocal leukoencephalopathy associated with cocaine use may have an inflammatory/immune basis,
possibly related to levamisole contamination, at least in some patients. Three cases, including the present two, have been
described wherein good neurological improvement was seen in association with steroid treatment. However, in the
absence of appropriate clinical trials, it remains unknown whether immunotherapy is truly beneficial for these patients.
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Background
Three major categories of cocaine-induced brain injury
have been described.
Vascular pathology is a well-recognized consequence
of cocaine abuse and includes ischemic and hemor-
rhagic stroke. Underlying mechanisms include vaso-
spasm, heightened sympathetic drive, acute hypertension,
cardioembolism and, in rare cases, vasculitis [1]. Even in
the absence of a history of cerebrovascular symptoms,
compared to control populations an increased prevalence
and severity of asymptomatic white matter lesions on
magnetic resonance imaging (MRI) has been documented
in cocaine users; these lesions are also thought to have an
ischemic basis [2, 3].
A second mechanism of cocaine-induced brain injury
is metabolic in nature. In particular, several cases of
acute/subacute cocaine-induced leukoencephalopathy
have been reported. Magnetic resonance imaging
(MRI) in these patients showed bihemispheric white
matter fluid-attenuated inversion recovery (FLAIR) and T2
signal abnormalities, spared U fibers, absent restricted
diffusion, absent gadolinium enhancement, increased lactate
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and decreased N-acetylaspartate peaks on MR spectroscopy
[4–8]. Histologically, there was widespread demyelination
with vacuolar degeneration and axonal loss [7, 8]. These
MRI, nuclear magnetic resonance (NMR) spectroscopy, and
histological features resemble heroin-induced toxic leu-
koencephalopathy (“chasing the dragon”), with the notable
exception that the occipital predominance and cerebellar
and brainstem involvement typical of heroin leukoence-
phalopathy was not seen. Both cocaine- and heroin-
induced leukoencephalopathies are thought to be associ-
ated with mitochondrial dysfunction [6–9].
More recently, a third type of cocaine-induced enceph-
alopathy was proposed by Gilbert who speculated that
an adulterant, levamisole, now commonly found in co-
caine, may cause acute and recurrent white matter le-
sions [10]. When used alone as a therapeutic agent, and
even after a single dose, levamisole can cause multifocal
inflammatory leukoencephalopathy with variable delay
in symptom onset ranging from one day to many weeks
[11–17]. An immune-mediated mechanism is postulated.
However, a recent review of 203 cases of cocaine users
who suffered complications attributed to levamisole con-
tamination, such as neutropenia and dermatological disor-
ders in particular, found no cases of leukoencephalopathy
[18]. In contrast, two recent cases of cocaine-related leu-
koencephalopathy were reported wherein the question
of levamisole toxicity was specifically raised [19, 20]. In
addition, it seems possible that some cases of cocaine-
related leukoencephalopathy previously postulated to
have a metabolic basis may have been related to levami-
sole contamination.
The present report describes two cocaine users with
multifocal white matter lesions who were treated with
steroids and plasma exchange, and subsequently im-
proved. The potential relationship of their presentations
to inflammatory white matter disease is discussed.
Case presentation
Case 1
A 25-year-old man with history of cocaine use presented
to the emergency room with left-sided upper and lower
limb weakness as well as sensory impairment involving
the face. Symptoms evolved such that he was bed-ridden
after 48 h. He had no history of previous neurological or
systemic symptoms. Computed tomography (CT) of the
brain showed bilateral periventricular hypodensities. CT
angiography of cervical and intracranial vessels was un-
remarkable. An MRI study of the brain demonstrated
increased FLAIR signal deep in the right and left hemi-
spheres (Fig. 1a), which also displayed patchy gadolinium
enhancement (Fig. 1b) and restricted diffusion (Fig. 1c–d).
Five days after admission he developed swallowing diffi-
culty, dysarthria, and confusion. In addition to the previ-
ously noted MRI abnormalities, repeat imaging showed
new lesions in the left internal and external capsules,
putamen and corona radiata, right medial pons and left
cerebellar peduncle, with heterogenous gadolinium en-
hancement (Fig. 1e–f ). The neuroradiological impression
was that the lesions were most compatible with demye-
linating disease. A urine screen was positive for co-
caine, cannabinoids, and oxycodone, and negative for
amphetamine, methadone, benzodiazepines, and barbi-
turates. Other investigations included the following nor-
mal or negative results: complete blood count, serum
electrolytes, urea, creatinine, glucose, erythrocyte sedi-
mentation rate, antinuclear antibodies, rheumatoid factor,
perinuclear and cytoplasmic anti-neutrophil cytoplasmic
antibodies (pANCA and cANCA respectively), extractable
nuclear antigens, lupus inhibitor, C3, C4, CH50, urinalysis,
vitamin B12, angiotensin converting enzyme level, thyroid
stimulating hormone level, free T3 and T4, cortisol level,
lipid profile, very long chain fatty acids, viral serology for
HIV, CMV, Hepatitis A, B, and C, Lyme serology, syphilis
screen, blood screen for salicylate, acetaminophen, and
ethanol. Liver enzymes (AST, ALT and GGT) were mild to
moderately elevated and subsequently normalized over a
period of six months. Cerebrospinal fluid (CSF) results
included: slightly elevated protein at 0.50 g/l (normal
0.20–0.40 g/l), normal glucose and chloride, normal total
cell count (3 × 106/l), negative oligoclonal bands, normal
IgG index, elevated albumin index at 9.0 (2.7–4.7), nega-
tive cryptoccocal antigen, negative cultures for bacteria
and fungi, negative polymerase chain reaction (PCR)
studies for CMV and HSV 1–2, and normal cytology.
He was treated with intravenous methylprednisolone,
1000 mg daily for five consecutive days, and subse-
quently underwent plasma exchange. During plasma ex-
change his neurological condition stabilized and he
subsequently achieved good, albeit partial, recovery. At
three months follow-up he had mild residual left-sided
hemiplegia but was otherwise independent in activities
of daily living and starting to return to work. Follow up
MRI five months after presentation showed reduction in
the size of lesions, no enhancement, and no new lesions
(Fig. 1g–h). MRI 21 months after the initial presentation
also showed no new lesions (not shown).
Case 2
A 41-year-old woman presented to the emergency room
of another hospital with recent confusion and impaired
balance. She had been using cocaine daily for seven
months. MRI FLAIR images showed multiple white
matter signal changes in both cerebral hemispheres in a
predominantly periventricular distribution (Fig. 2a–c)
sparing the corpus callosum, cerebellum and brainstem.
Restricted diffusion was present in many lesions (not
shown). Subtle gadolinium enhancement was present in a
few lesions (not shown). She was treated with supportive
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care for one week and then discharged with partial recov-
ery. She resumed cocaine use and was then admitted to
our centre six weeks after the previous hospital discharge
because of worsening neurological symptoms. She was
completely bedridden with inability to walk, incontin-
ence, severely impaired communication skills, behavioural
problems, cognitive impairment, and multifocal neuro-
logical deficits. MRI FLAIR images showed marked pro-
gression compared to the previous study. Confluent white
matter abnormalities involved both cerebral hemispheres
(Fig. 2d–e). There was subtle scattered restricted diffusion
and no gadolinium enhancement. Urine testing was
Fig. 1 Case 1: MR images of brain lesions. a On admission a large area of increased FLAIR signal is present in the right lentiform nucleus, internal
capsule, thalamus, corona radiata and centrum semiovale and a small signal focus is present in the left internal capsule/globus pallidus region.
b A rim of gadolinium enhancement is present. c Restricted diffusion is shown by diffusion-weighted imaging in conjunction with the ADC map
(d). e and f Five days later FLAIR images show additional lesions in the right medial pons, left cerebellar peduncle, putamen and corona radiata.
Five months later, all lesions are smaller (g) and non-enhancing (h)
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positive for cocaine, oxycodone, opiates, benzodiazepines,
tramadol and citalopram, and negative for cannabinoids,
amphetamine and methadone. Other investigations in-
cluded the following normal or negative results: complete
blood count, electrolytes, glucose, liver enzymes, thyroid
stimulating hormone, T3, T4, creatinine kinase, angioten-
sin converting enzyme, HIV, Hepatitis A, B, and C screens,
Lyme serology, syphilis screen, blood screen for salicylates,
acetaminophen and ethanol. The serum creatinine was
elevated (137 micromoles/l) as was the urea (7.6 milli-
moles/l). Serum albumin was low (29 g/l). The erythro-
cyte sedimentation rate ranged from 22 to 64 on
multiple samplings, C-reactive protein was elevated at
11 mg/l while antinuclear antibodies, pANCA, cANCA,
C3, C4, NMDA receptor and anti-thyroid peroxidase
antibodies were normal. The vitamin B12 level was low
at 166 picomole/l (normal >180). Copper, zinc and ce-
ruloplasmin levels were normal. CSF protein was
slightly elevated at 0.48 g/l. The glucose, chloride and
cell count (4 × 106/l) were normal. No CSF acid fast ba-
cilli were seen and cultures for bacteria and fungi were
negative. CSF PCR for CMV and HSV1–2 were nega-
tive. She was treated with intravenous methylpredniso-
lone, 1000 mg/day for five days, and plasma exchange.
She showed substantial, albeit partial, recovery soon
thereafter which continued over the course of several
months. At four months follow-up multiple domains of
cognitive function were improved but she had some re-
sidual deficits in attention, calculation, and visuospatial
function. She was independent with respect to walking
and most activities of daily living. Follow-up MRI at
that time showed improvement of the subcortical and
periventricular signal abnormalities and no new lesions.
Similarly, no new lesions were seen on MRI 13 months
after presentation (not shown).
Discussion
Only a few cases of cocaine-related leukoencephalopathy
have been reported [4–8, 21]. The clinical and MRI fea-
tures of our two patients suggest that primary vascular
mechanisms, which produce the more commonly recog-
nized acute stroke complications of cocaine use, are un-
likely. Therefore, the present cases are best considered
examples of cocaine-related leukoencephalopathy.
The pattern of white matter involvement in our pa-
tients, including both multifocal periventricular and con-
fluent bihemispheric distribution, sparing subcortical U
fibers, is similar to imaging results in previous reports of
cocaine-induced leukoencephalopathy [4, 6–8]. Because
of similarities to heroin-induced leukoencephalopathy,
including MR spectroscopy, previous reports speculate
that an underlying metabolic derangement, mitochon-
drial dysfunction in particular, is the substrate of these
toxic leukoencephalopathies. Thus, the white matter le-
sions in our patients may have a similar mechanism.
However, our patients also share features with patients
who develop leukoencephalopathy secondary to levami-
sole [13–17]. Originally developed in the 1960s as an anti-
helminthic agent, levamisole also has immune modulating
properties and has been used in the treatment immune-
mediated and inflammatory disorders such as rheumatoid
arthritis, nephritic syndrome, inflammatory bowel disease,
and aphthous ulcers, among other conditions. MRI
characteristics of levamisole-related brain lesions include
Fig. 2 Case 2: MR images (FLAIR) of brain lesions. a-c On admission foci of increased signal are present in the white matter of the cerebral
hemispheres bilaterally, predominantly in a periventricular distribution. d-f Repeat imaging seven weeks later, after further neurological deterioration,
shows prominent interval progression of signal abnormality in the subcortical and periventricular white matter
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hyperintense T2 and FLAIR signal and, variably, diffusion-
weighted signal abnormality, gadolinium enhancement
and/or surrounding edema [11, 15–17]. The white matter
lesions are typically found in subcortical and periventricu-
lar white matter, but brainstem and cerebellar involvement
can also occur, as was the case in both of our patients.
Distinction between levamisole leukoencephalopathy,
multiple sclerosis and acute disseminated encephalitis,
by imaging features alone can be difficult [16, 17, 21].
Brain biopsy of levamisole-induced lesions demonstrates
active demyelination including myelin loss and accu-
mulation of perivascular lymphocytes [12, 16]. Most
cases reported in the literature have received steroid
[13, 14, 16, 17] or steroid combined with plasmapheresis
[11] or immunoglobulin [15], and typically have shown
good outcomes. However, if treated late, for instance eight
months after levamisole ingestion and onset of symptoms,
no improvement is seen [22].
Levamisole has immuno-stimulant properties that in-
crease endogenous opiate levels in the brain and alter
monoaminergic function [23]. These properties may be
related, at least in part, to its popularity as a cocaine
adulterant. It was first detected in cocaine samples in
2003 and by 2009 was present in over 70 % of cocaine
specimens tested by the United States Drug Enforce-
ment Agency [24]. In one study, among urine samples
testing positive for cocaine, 68 % were also positive for
levamisole [24].
Urine levamisole levels were not tested in our patients,
and therefore the possibility that levamisole is respon-
sible for their presentation is not proven. It is possible
that cocaine alone may have produced white matter le-
sions through immune-mediated or other mechanisms,
independent of levamisole contamination. Cocaine alters
endothelial function thereby facilitating migration of im-
mune cells into the central nervous system, increases
the secretion of pro-inflammatory cytokines, and en-
hances the development of acute experimental allergic
encephalomyelitis [25].
Similar to patients with levamisole-induced multifocal
leukoencephalopathy, steroid treatment of a patient with
cocaine-related recurrent leukoencephalopathy was “help-
ful” according to González-Duarte and Williams [20]. On
the other hand recurrent episodes of leukoencephalopathy
in another cocaine abuser remitted with and without ster-
oid treatment [6].
Conclusion
The clinical and MRI improvement observed in our
patients, subjected to steroids and plasmapheresis,
supports the concept of an immune-mediated mechan-
ism, possibly levamisole-induced, underlying cocaine
neurotoxicity in some patients. However, to the best of
our knowledge there have been no controlled trials of
immunotherapy for the treatment of cocaine-induced
leukoencephalopathy. Therefore, extreme caution is
warranted interpreting these limited observations, es-
pecially given the fact that inflammatory white matter
disease (for example multiple sclerosis) can display
spontaneous remission. In addition, given the preva-
lence of cocaine use in the general population, patients
presenting with white matter disease suggestive of
acute disseminated encephalomyelitis or multiple scler-
osis, with or without remissions and relapses, should be
carefully reviewed with respect to cocaine use.
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